Nausea
Nausea is the single most-discussed side effect in retatrutide communities — and the most common reason people reduce or discontinue. This page covers what the clinical data shows, community-reported mitigation strategies, and what actually has evidence behind it.
Community mitigation strategies (timing injections, dietary changes, anti-nausea medications) are not clinically validated for retatrutide specifically. Consult a physician before using any medication to manage side effects.
Common Claims — Fact-Checked
These claims appear frequently in community discussions. Each is evaluated against the best available clinical evidence.
"Injecting at night reduces nausea."
?Insufficient EvidenceWidely reported in communities as a strategy. No clinical trial has tested injection timing as a nausea mitigation. Plausible pharmacologically (peak plasma levels occur 24–48 hours post-injection), but unvalidated.
"Eating before injecting prevents nausea."
?Insufficient EvidenceCommunity consensus but no controlled data. Some participants report it helps; others report no difference. The mechanism is unclear given retatrutide's weekly dosing and multi-day half-life.
"Nausea means the drug is working."
✗UnsupportedNausea is an adverse effect of GI motility changes, not a marker of efficacy. Weight loss and nausea are independent outcomes. Participants without nausea can achieve equivalent weight loss.
Evidence Summary
TRIUMPH Phase 3: nausea reported in approximately 40–55% of participants at the 12 mg dose, predominantly during escalation phases. Rates declined significantly after reaching maintenance dose. Discontinuation due to GI AEs was approximately 5–8% across trials.
Analyzed Threads
These threads were selected for editorial analysis. TryTrutide does not link to Reddit posts.
"Nausea is way worse than Ozempic — almost quit in week 2"
~Partially SupportedClaim: Users switching from semaglutide (Ozempic/Wegovy) to retatrutide report significantly worse nausea, particularly in the first 4–8 weeks, attributing this to the addition of glucagon receptor agonism.
The Phase 2 retatrutide trial reported nausea in 42% of participants on the 12 mg dose versus approximately 20–25% for semaglutide 2.4 mg in the STEP trials. The higher nausea rate is likely attributable to the triple agonist mechanism — glucagon receptor activation has independent emetic effects in addition to GLP-1-mediated nausea. However, direct head-to-head comparisons do not exist, and individual variation is substantial. The community observation of worse nausea than semaglutide is consistent with the clinical data, though the characterization of it being "way worse" reflects individual experience rather than a universal finding.
"Hair loss is real and nobody talks about it"
?Context NeededClaim: A significant number of users report noticeable hair shedding starting around weeks 8–16, attributed to retatrutide. Some claim it is worse than with semaglutide or tirzepatide.
Hair loss (telogen effluvium) is a well-documented consequence of rapid weight loss, not a direct drug effect. It occurs when the body redirects resources away from non-essential functions during caloric restriction. The same phenomenon is reported with semaglutide and tirzepatide. The TRIUMPH-Obesity trial listed alopecia as an adverse event in approximately 5% of participants on the 12 mg dose versus 1% on placebo — a real signal, but likely mediated by weight loss magnitude rather than the drug mechanism itself. Users losing weight faster with retatrutide may experience more pronounced telogen effluvium.
Reddit Observatory
26 topic categories — community claims vs. clinical evidence
Want a Physician to Review Your Eligibility?
Retatrutide is not yet FDA approved. A physician can review your health profile and discuss investigational access options.
Start Physician Review